Finance

Lists
Why is QNCX up 8.07%?
Dive Deeper
QNCX:NASDAQ
Quince Therapeutics Inc
$ 31.73
+8.07%
(+2.37) 1D
10-р сарын 9, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QNCX...
Open
$ 30.50
High
$ 37.00
Low
$ 29.84
Mkt. cap
32.27 сая
Avg. vol.
22.66 мян
Volume
138.74 мян
52-wk high
$ 909.98
52-wk low
$ 15.10
EPS
-$ 125.71
Beta
1.33
Shares outstanding
1.02 сая
No. of employees
38
Open
$ 30.50
High
$ 37.00
Low
$ 29.84
Mkt. cap
32.27 сая
Avg. vol.
22.66 мян
Volume
138.74 мян
52-wk high
$ 909.98
52-wk low
$ 15.10
EPS
-$ 125.71
Beta
1.33
Shares outstanding
1.02 сая
No. of employees
38
News stories
From web sources and news partners
About Quince Therapeutics Inc
CEO-
Employees38
Founded2012
HeadquartersSouth San Francisco, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 8 analysts giving stock ratings to QNCX in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for QNCX in the last 3 months.
Highest
Current $ 31.73
$ 98.00 (+208.86%)
Average
$ 75.63 (+138.35%)
Lowest
$ 68.00 (+114.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
$ 72.00
+126.9%
10/09/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$ 98.00
+208.9%
09/30/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$ 68.00
+114.3%
09/29/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$ 68.00
+114.3%
09/30/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$ 70.00
+120.6%
09/24/2026
Jonathan Wolleben
Citizens JMP
Buy
Upgraded
$ 77.00
+142.7%
09/22/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Reiterated
$ 70.00
+120.6%
08/17/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$ 82.00
+158.4%
08/17/2026
Jason McCarthy
Maxim Group
Hold
Downgraded
-
-
02/02/2026
Elemer Piros
Lucid Capital
Sell
Downgraded
-
-
01/30/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
01/30/2026
Last report
2026 оны 8-р сарын 14
Fiscal period
Q2 2026
-$ 12.15 / -$ 12.39
+1.88%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.08 сая
12.60 сая
6.84 сая
5.46 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.28 сая
3.64 сая
4.27 сая
16.63 сая
Operating expense
11.36 сая
16.24 сая
11.11 сая
22.09 сая
Total operating expenses
11.36 сая
16.24 сая
11.11 сая
22.09 сая
Operating income
-11.36 сая
-16.24 сая
-11.11 сая
-22.09 сая
Other non operating income
191.00 мян
-17.12 сая
32.84 сая
3.78 сая
EBT including unusual items
-13.49 сая
-36.31 сая
30.57 сая
-75.41 сая
EBT excluding unusual items
-10.87 сая
-32.65 сая
21.88 сая
-17.72 сая
Income tax expense
-46.00 мян
3.15 сая
-5.34 сая
75.00 мян
Effective tax rate
0.34%
-8.66%
-17.46%
-0.10%
Other operating expenses
-
-
-
-
Net income
-13.44 сая
-39.46 сая
35.91 сая
-75.49 сая
Net profit margin
-
-
-
-
Earnings per share
-50.00
-152.00
57.60
-12.15
Interest and investment income
300.00 мян
227.00 мян
160.00 мян
584.00 мян
Interest expense
-
-
-
-
Net interest expenses
300.00 мян
227.00 мян
160.00 мян
584.00 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.33 сая
-16.20 сая
-11.08 сая
-22.05 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс